说明:双击或选中下面任意单词,将显示该词的音标、读音、翻译等;选中中文或多个词,将显示翻译。
您的位置:首页 -> 词典 -> Fas配体/Fas途径
1)  FasL/Fas pathway
Fas配体/Fas途径
2)  Fas/Fas ligand
Fas/Fas配体
1.
Effects of Interleukin-10 on the proliferation and Fas/Fas ligand expression of hepatic stellate cells.;
白细胞介素-10对肝星状细胞增殖及表达Fas/Fas配体的影响
3)  Fas/FasL
Fas/Fas配体
1.
Aim: To investigate the effect of ligustrazini(LGT) on expression of Fas/FasL mRNA during pulmonary ischemia/reperfusion injury(PI/RI) in the rabbits.
每组又分为再灌注1h3、h、5 h三个亚组,每个亚组10只,分别于再灌注1 h3、h、5 h三个时点取左肺组织,观察Fas/Fas配体(Fas/FasL)mRNA定位表达、凋亡指数(AI)、肺组织湿、干重比(W/D)、肺损伤组织学定量评价指标(IQA)及光镜、电镜下的组织形态学改变。
2.
Objective To investigate the effect of L-arginine (L-Arg) on expression of Fas/FasL mRNA during pulmonary ischemia and reperfusion injury (PIRI) in the rabbits.
分别于再灌注3h取左肺组织,观察Fas/Fas配体(Fas/FasL)mRNA定位表达、凋亡指数(AI)、肺组织湿干质量比(W/D)、肺损伤组织学定量评价指标(IQA)及光镜、电镜下的组织形态学改变。
3.
METHODS: Expression of Fas/FasL protein and mRNA was detected using immunohistochemistry and in situ hybridization, respectively.
目的 :观察内毒素急性肝损伤后肝细胞凋亡和Fas/Fas配体 (FasL)表达的变化 ,以及氟美松对其影响 ,探讨急性肝损伤早期作用机制 。
4)  Fas pathway
Fas途径
5)  Fas ligand
Fas配体
1.
The nole of Fas ligand positive testicular cells in systemic and local immunologic previlege for survival of co-transplanted islet cells;
Fas配体阳性睾丸细胞对共移植的胰岛细胞存活起全身和/或局部的免疫豁免作用
2.
Expression of Fas ligand and T cell intracellular antigen-1 during acute rejection after renal transplantation;
移植肾急性排斥时Fas配体和T细胞内抗原1的表达
3.
Relevance of fas ligand expression in cervical adenocarcinoma lymph node metastasis and prognosis.;
宫颈腺癌中Fas配体的表达对淋巴结转移和预后的影响
6)  FasL
Fas配体
1.
The expression of FasL and ICAM-1 on the HEVs in the hypertrophic tonsils;
Fas配体和细胞黏附分子1在肥大扁桃体组织高内皮小静脉中的表达及意义
2.
The Changes of Peripheral Serum sFas and FasL in Heroin Addicts;
海洛因依赖患者外周血清可溶性Fas及Fas配体的变化
3.
Mechanism of tolerance inducement in rat liver transplantation by constructing retroviral vector containing FasL gene;
转Fas配体基因的树突状细胞在诱导大鼠肝移植免疫耐受中的作用
补充资料:[3-(aminosulfonyl)-4-chloro-N-(2.3-dihydro-2-methyl-1H-indol-1-yl)benzamide]
分子式:C16H16ClN3O3S
分子量:365.5
CAS号:26807-65-8

性质:暂无

制备方法:暂无

用途:用于轻、中度原发性高血压。

说明:补充资料仅用于学习参考,请勿用于其它任何用途。
参考词条